Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Pfizer’s trading volume surged to $13.51 billion, more than doubling from the prior day. Despite the impressive spike in ...

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Pfizer PFE has committed significant resources for the development of treatments in the fields of oncology, internal medicine, immunology, inflammation and vaccines. Over the past decade, Pfizer has ...

Though indexes have rebounded, the first half of the year has been rocky for investors. The market had to digest a variety of uncertainties, from geopolitical problems to mixed economic data and the U ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on ...

Pfizer’s oncology revenues grew 7% on an operational basis in the first quarter of 2025, driven by drugs like Xtandi ... Going by the price/earnings ratio, the company’s shares currently trade at 7.77 ...

In October, Pfizer reported that quarterly growth in oncology revenues had reached 54%, driven by Ibrance, Analysts on earnings calls showered executives with compliments — “great launch ...